Shares of Celgene Corporation (CELG) Drops by -2.08%

Celgene Corporation (CELG) has risen sharply, recording gains of 4.16% in the past 4 weeks. However, the stock has corrected -2.08% in the past 1 week, providing a good buying opportunity on dips. Celgene Corporation (CELG) : During the past 4 weeks, traders have been relatively bearish on Celgene Corporation (CELG), hence the stock is down -0.2% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -3.52% relative to the S&P 500. The stock has recorded a 20-day Moving Average of 2.55% and the 50-Day Moving Average is 0.78%.

Celgene Corporation (NASDAQ:CELG): During Fridays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $102.37 and $102.17 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $104.56. The buying momentum continued till the end and the stock did not give up its gains. It closed at $102.85, notching a gain of 1.41% for the day. The total traded volume was 5,423,844 . The stock had closed at $101.42 on the previous day.


The company Insiders own 0.97% of Celgene Corporation shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -6.26% . Institutional Investors own 81.36% of Celgene Corporation shares. During last six month period, the net percent change held by insiders has seen a change of -7.12%. In a related news, Hugin Robert J, director officer (see remarks) of Celgene Corp /De/, unloaded 75,000 shares at an average price of $100.16 on June 20, 2016. The total amount of the transaction was worth $7,512,000, according to the disclosed information with the Securities and Exchange Commission in a Form 4 filing.

Celgene Corporation (Celgene), together with its subsidiaries, is an integrated biopharmaceutical company engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. The Companys primary commercial stage products include REVLIMID (lenalidomide), ABRAXANE, POMALYST/IMNOVID, VIDAZA, azacitidine for injection (generic version of VIDAZA), THALOMID (sold as THALOMID or Thalidomide Celgene outside the United States), OTEZLA (apremilast) and ISTODAX (romidepsin). Celgene is involved in research in a range of scientific areas designed to deliver therapies, targeting areas, including intracellular signaling pathways, protein homeostasis and epigenetics in cancer and immune cells, immunomodulation in cancer and autoimmune diseases, and therapeutic application of cell therapies.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *